HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial.

AbstractOBJECTIVE:
To test the safety, tolerance, and efficacy of extended-release niacin monotherapy on dyslipidemia in persons with chronic tetraplegia.
DESIGN:
Placebo-controlled, blinded, multicenter, randomized controlled trial.
SETTING:
Three spinal cord injury research/rehabilitation centers.
PARTICIPANTS:
Persons with chronic tetraplegia (N=54) and low plasma high-density lipoprotein cholesterol (HDL-C) levels.
INTERVENTION:
Extended-release niacin monotherapy (48 weeks; n=31) on a dose-titration schedule versus matched placebo (n=23).
MAIN OUTCOME MEASURES:
Safety was assessed by using percentages of treatment-emergent adverse events and increased levels of hepatic transaminases, uric acid, glycosylated hemoglobin, and fasting glucose. Tolerance was assessed by using participant reports for frequency and intensity of adverse effects of extended-release niacin. Primary effectiveness outcomes were fasting HDL-C level and plasma total cholesterol (TC)/HDL-C ratio. Secondary outcomes included plasma low-density lipoprotein cholesterol (LDL-C) and TC levels and LDL-C/HDL-C ratio.
RESULTS:
Significant increases in fasting HDL-C levels (24.5%) were accompanied by decreases in TC/HDL-C and LDL-C/HDL-C ratios, LDL-C levels, and TC levels (all P<.05). No evidence of sustained hepatotoxicity or hyperglycemia was observed. Treatment-emergent withdrawals (12.9%) accompanied flushing (n=1), hypotension/presyncope (n=1), and diarrhea (n=2). One subject experienced transient hyperuricemia. Other drug-reported symptoms did not differ from those for placebo.
CONCLUSIONS:
Extended-release niacin monotherapy is safe, tolerated, and effective for most persons with chronic tetraplegia. Special precautions for changes in bowel habits and postadministration hypotension should be observed.
AuthorsMark S Nash, John E Lewis, Trevor A Dyson-Hudson, Yaga Szlachcic, Florence Yee, Armando J Mendez, Ann M Spungen, William A Bauman
JournalArchives of physical medicine and rehabilitation (Arch Phys Med Rehabil) Vol. 92 Issue 3 Pg. 399-410 (Mar 2011) ISSN: 1532-821X [Electronic] United States
PMID21276961 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2011 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Delayed-Action Preparations
  • Hypolipidemic Agents
  • Triglycerides
  • Niacin
  • Cholesterol
Topics
  • Adolescent
  • Adult
  • Aged
  • Cholesterol (blood)
  • Chronic Disease
  • Delayed-Action Preparations
  • Double-Blind Method
  • Dyslipidemias (complications, drug therapy)
  • Female
  • Humans
  • Hypolipidemic Agents (administration & dosage, adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Niacin (administration & dosage, adverse effects, therapeutic use)
  • Quadriplegia (complications)
  • Triglycerides (blood)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: